Tag: the war on (some) drugs

Veterans deserve change. US should reschedule cannabis now.

When our nation’s heroes return home, they often face a quiet suffering — something I have seen happen so often in my peers. As a combat veteran and an advocate for those who have worn the uniform, I know that so many of us face these challenges long after we return home. Post-traumatic stress (PTS) is a battlefield of its own — invisible, relentless, and too often fought alone.

Over the years, I’ve dedicated my life to improving the lives of our veterans, whether serving as a Veterans Fellow and Lead Policy Advisor on Military and Veterans Affairs to Sen. Chuck Grassley, leading within the Iowa Veterans of Foreign Wars (VFW), or conducting academic research focused on veterans’ issues. One thing has become undeniably clear: it’s time to reschedule cannabis as a Schedule III substance under federal law, a change that is backed by President Donald Trump, which would open the door for unlocking its therapeutic potential for veterans suffering from PTS and other chronic illnesses.

Currently, cannabis remains a Schedule I substance — the same category as heroin — defined as having “no accepted medical use” and a “high potential for abuse.” This is not only scientifically outdated, but also morally indefensible. Veterans are not asking for a miracle cure. We are asking for options. We are asking for the freedom to explore alternative treatments when conventional therapies — prescription medications, talk therapy, or exposure therapy — fall short. For many veterans, they do. And for some, cannabis has helped where nothing else has.

Keep reading

High Doses Of LSD Lead To ‘Greater Reductions In Depression’ Compared To Low Doses Of The Psychedelic, New Study Finds

Taking a high dose of LSD, coupled with assisted therapy, led to “greater reductions in depression” among patients compared to those who received a low dose of the psychedelic, according to a new study.

Researchers at the University of Basel in Switzerland investigated the therapeutic potential of LSD for people with moderate-to-severe major depressive disorder, and they found the substance showed “promise” as a “novel approach” to treating the condition.

Notably, the study—published this month in the journal Med—indicated that “high-dose-LSD-assisted therapy reduced depressive symptoms more than low-dose therapy” and that the improvements lasted for up to 12 weeks after the treatment.

The randomized, double-blind trial involved administering doses of 100μg and 200μg of LSD for one cohort and two doses of 25μg of the psychedelic for the other. Symptoms of depression were measured at multiple intervals, starting with the baseline and followed up with examinations after two weeks, six weeks and 12 weeks.

After assessing the 61 patients post-administration, the researchers concluded that the “findings of this exploratory study support further investigation of LSD-assisted therapy in depression in a larger phase 3 trial.”

“The present trial’s strengths include a clinically representative sample with respect to the duration of illness, common comorbid conditions, and various pretreatments,” the study authors said. “Other strengths include the comparison with a low-dose group and a relatively long follow-up period of 12 weeks after the last administration.”

“LSD could be used safely within the framework of this study,” they said, adding that compared to previous trials involving psilocybin, “LSD has a longer duration of action.”

“This prolonged effect makes clinical application more resource intensive. It remains to be resolved whether this extended duration offers clinical advantages,” the study text says. “Furthermore, it is yet to be determined if there are other relevant differences among hallucinogenic drugs in terms of therapeutic potential.”

Keep reading

DEA Judge Shuts Down Cannabis Manufacturing Case Without Hearing, Company Plans Legal Challenge

The company behind the application, MMJ BioPharma Cultivation, is now preparing to challenge the ruling in federal court and call for the judge’s recusal.

The ruling was issued by DEA Chief Administrative Law Judge John Mulrooney II, who dismissed the company’s bid for a marijuana bulk manufacturing license after more than six years of delays. MMJ BioPharma said the decision came without warning and without any opportunity to present evidence or respond to agency claims—calling it a “procedural ambush.”

“This isn’t regulation—it’s an illegal ambush,” said MMJ CEO Duane Boise, who said the company had complied with all requirements under the Controlled Substances Act and FDA pathways.

MMJ, which is developing cannabis-based medicines for Huntington’s disease and multiple sclerosis, submitted a legally binding supply agreement in March 2024 with a DEA-licensed Schedule I facility. The agreement included specific sourcing protocols, defined volume, and DEA Form 222 compliance. Despite that, Mulrooney’s June 16 ruling ignored the document entirely and blocked it from being entered into the record.

Boise accused the DEA of demanding the agreement and then refusing to acknowledge it once submitted. “The agency cannot demand a document, receive it, then declare it irrelevant behind closed doors,” he said.

The order also reversed a previous determination by another administrative judge that certain disputed facts warranted a hearing. Instead, Mulrooney cited internal communications from a DEA investigator that MMJ was never allowed to challenge or respond to—raising concerns of ex parte communications and due process violations.

Keep reading

Why Is Texas Supporting Psychedelics Research While Criminalizing Cannabis?

Texas just announced it will invest $50 million into studying ibogaine, a powerful psychedelic drug that remains illegal at the federal level. The goal? To develop it into a potential Food and Drug Administration-approved treatment for conditions like opioid use disorder, PTSD and depression; especially among veterans.

On the surface, this might sound like a bold and progressive move. But here’s the irony: at the very same time, Texas continues to criminalize cannabis and might soon even outlaw hemp-derived THC products.

Let’s break this down. Cannabis, a plant with centuries of use, decades of medical data and broad public support remains illegal for adult use in Texas. Despite overwhelming national support for legalization—a staggering 88 percent of Americans now back medical or recreational cannabis use)—the state has chosen to double down on prohibition, with lawmakers sending Gov. Greg Abbott (R) a bill that would outlaw consumable hemp products with any traces of THC. He has until Sunday to decide whether to allow that ban to take effect.

Even worse, prohibition isn’t stopping anything. The black market is thriving in Texas. Cartels and illicit operators flood the state with unregulated, untested cannabis. No taxes are collected, no consumer protections exist and legal hemp retailers are now being threatened. It is a misguided public safety argument deluded by a lack of facts and science, political conservatism, contradictory business objectives and outdated stigmas.

Meanwhile, ibogaine, a hallucinogenic alkaloid that can induce intense psychedelic experiences, is now the subject of a $50 million state-funded research push. The same lawmakers who claim cannabis is too dangerous and not well studied are throwing their support behind a compound with far less research and much more uncertainty with the intent of studying it.

This isn’t a critique of psychedelic medicine. Ibogaine may very well hold incredible therapeutic value. But if Texas is willing to support cutting-edge, controversial treatments for serious mental health and addiction issues, why not start with widely available data and access to cannabis? Cannabis has already been shown to help with chronic pain, anxiety, sleep, seizures and opioid dependency.

Keep reading

75,000 pounds of THC products seized in DFW raids as Texas Gov. Abbott weighs statewide ban

Police raided locations across DFW on Tuesday in a year-long investigation into THC sales. 

The Allen Police Department, with help from the DEA, seized products at three warehouses in Dallas, while other agencies raided the owners’ homes in Carrollton, Colleyville, and Plano.

Allen’s police chief took the CBS News Texas crew inside one of the warehouses as officers pulled products off the shelves. 

According to early estimates from Allen PD, investigators seized over 75,000 pounds of THC products and $7 million worth of cash and assets in Tuesday’s raids.   

Chief Steve Dye said the warehouse raids are the product of an investigation that began more than a year ago with undercover purchases at shops in Allen. The I-Team documented how the Allen Police Department’s narcotics unit bought and tested the items ahead of raids at nine stores last August. Investigators said the illegal products found in Allen are being supplied by the warehouses in Dallas. 

“You don’t have to go to your drug dealer anymore to buy drugs,” said Dye. “You can go to a vape shop on any corner.” 

He believes the products found on store shelves are more dangerous than illegal drugs because, Dye said, the false sense of safety has led to an explosion in use.

Keep reading

Ohio GOP Lawmakers Can’t Agree On How To Amend Marijuana Law, Causing Planned Vote To Be Canceled

Despite efforts in the Ohio legislature to pass a bill to significantly change the state’s voter-approved marijuana law, last-minute disagreements between the House and Senate Republicans seemed to have derailed that plan for now—with House lawmakers signaling that a deal won’t be struck before the summer recess.

After taking public testimony and adopting certain changes to the Senate-passed legislation, SB 56, in recent weeks, the House Judiciary Committee ultimately declined to advance the proposal as scheduled at a Wednesday hearing, making it so the measure couldn’t advance to a floor vote planned for that day. Evidently, the revisions didn’t sit well with key senators, according to several legislators.

“Apparently the Senate changed their mind,” Rep. Jamie Callender (R), a pro-legalization lawmaker, told News 5 Cleveland.

Changes approved at a hearing late last month, for example, rolled back some of the strict limits included in a version of the measure passed by the Senate in February, including a criminal prohibition on sharing marijuana between adults on private property.

“They wanted to make a mandatory jail sentence for passing a joint between friends,” Callender, who has spent weeks working on additional changes to the legislation, said. He also complained about the Senate’s proposal to put all cannabis tax revenue in the state’s general fund, which would have prevented local municipalities from getting a share of those dollars as is currently the law.

Keep reading

Federal Bill Would ‘Effectively’ Ban All Consumable Hemp Products—’Including CBD’—Congressional Researchers Say

A federal spending bill that’s advancing in the House would “effectively” prohibit hemp-derived cannabinoid products, including CBD, congressional researchers say.

In a report published by the Congressional Research Service (CRS) last week, legislative analysts looked at the potential impact of hemp-related provisions that advocates and stakeholders say would devastate a core sector of the industry.

While report language attached to the 2026 appropriations bill was recently amended to clarify lawmakers’ intent not to disrupt the non-intoxicating cannabinoid market—signaling that products like CBD shouldn’t be banned—the legislation itself hasn’t changed and could still jeopardize the industry without further amendments to its provisions.

The CRS analysis, which came out after the bill’s report language was revised, seems to validate the industry’s concerns about the legislation, explaining how it would “expand on the existing statutory definition of hemp,” which currently means cannabis containing no more than 0.3 percent THC by dry weight, “to include industrial hemp products and exclude hemp-derived cannabinoid products.”

“Excluding hemp-derived cannabinoid products from the federal definition of hemp effectively would prohibit production and sale of hemp-derived cannabinoids, derivatives, and extracts thereof, including cannabidiol (CBD),” it says. “Excluded cannabinoids would cover also non-naturally occurring and synthesized or manufactured compounds.”

“The proposed provision would make other broader changes to the hemp definition by changing the allowable limits of THC—the leading psychoactive cannabinoid in the cannabis plant—to be determined on the basis of its total THC, including tetrahydrocannabinolic acid (THCA), instead of delta-9 THC. This would codify the regulatory practice established in USDA’s 2021 final hemp regulations. The provision would exclude from hemp ‘any viable seeds from a Cannabis sativa L. plant’ that exceed a total THC (including THCA) of 0.3 percent in the plant on a dry weight basis.”

As it stands, the legislation has cleared a House Appropriations subcommittee—but while it was discussed in the full committee last week, members ultimately did not act on it before recessing for a district work period. The panel is set to take the bill back up next week.

Before breaking, however, the full panel did adopt a manager’s amendment to the attached report from Rep. Andy Harris (R-MD), a vocal opponent of cannabis reform. Despite his personal opposition, the revised report clarifies that the panel does not intend to prohibit non-intoxicating cannabinoid products with “trace or insignificant amounts of THC” that were federally legalized during the first Trump administration.

“In determining the quantifiable amounts, the Committee does not intend for industrial or nonintoxicating hemp-derived cannabinoid products with trace or insignificant amounts of THC to be affected,” it says.

Harris said in opening remarks at last week’s hearing that the legislation closes “the hemp loophole from the 2018 Farm Bill.”

Keep reading

Cannabis extract proves to be highly effective at killing the most dangerous animals in the world

Every year, mosquito-borne diseases cut short more than a million lives across the globe, outpacing every other animal threat to humanity. The rising toll has public-health teams scrambling for fresh combat tools, especially as traditional chemical sprays lose their edge.

That loss stems from two hard truths. First, the very pyrethroid insecticides that once worked wonders now linger in soil and water, nudging delicate ecosystems off balance.

Second, mosquitoes adapt fast. Larvae soaking in tainted puddles and adults drifting through treated neighborhoods increasingly shrug off doses that once killed them.

Controlling the pests at their waterborne stage is vital, yet options that stay potent without harming everything else remain limited.

Cannabis, CBD, and mosquitoes

Recent research published in the journal Insects points to a solution hiding in plain sight: the hemp plant, Cannabis sativa.

After air-drying and grinding ordinary hemp leaves, scientists at The Ohio State University led by Erick Martinez Rodriguez extracted cannabidiol (CBD) and added the concentrate to cups of water teeming with yellow fever mosquito larvae.

Within 48 hours, both a strain that laughs at common insecticides and a non-resistant strain were wiped out.

“Mosquitoes are one of the deadliest animals in the world, mainly because as adults they serve as vectors of disease,” Rodriguez explained.

From resistance to vulnerability

Two important findings jumped out. The first was total mortality: every mosquito larva exposed to sufficient CBD died by the two-day mark, regardless of its genetic armor.

The second was efficiency. While industrial chemicals often push resistance higher with every generation, CBD’s effect cut straight through those defenses. Doses varied, but even modest concentrations proved lethal to all mosquito larvae.

“If you compare the amount of hemp extract needed to kill 50 % of the population to other synthetic conventional insecticides, it is on the high side, but when you compare it side by side to other natural extracts we have tested in our lab, only a relatively low amount is required to produce high mortality values in larvae,” said Martinez Rodriguez.

Keep reading

Maine Legislature Passes Bill Creating Separate Licensing System for Sun-Grown Marijuana With Significantly Lower Fees

The legislation was approved by the Senate in a 21 to 14 vote, after clearing the House 110 to 35. The measure defines “sun-grown cultivation” and “sun-grown cultivator” under state law, applying to those who grow marijuana primarily using natural sunlight and limited artificial lighting.

The bill creates a separate licensing framework for outdoor cultivators, including significantly lower fees. For example, a Tier 4 outdoor cultivation license would cost $15,000 annually—half the cost of an equivalent indoor operation.

Under the proposed law, sun-grown caregivers would be allowed to grow up to 150 mature plants or use up to 2,500 square feet of canopy each year, expanding the current limits. Additional provisions include updated security requirements for cultivation facilities, a grace period for new employees awaiting ID card approval, and the elimination of yeast and mold testing requirements for adult-use marijuana.

Supporters say the measure promotes sustainability, lowers barriers for small growers, and reflects Maine’s agricultural roots. If signed into law, it would mark a significant shift in how the state regulates outdoor marijuana cultivation, and it would make Maine one of the only states with a designated license for sun-grown cannabis growers.

Keep reading

Legalization turns Germany into a cannabis hotspot: Mary Jane becomes the world’s largest cannabis trade fair for the first time

About a year after partial legalization by the “traffic light” government coalition, Germany has become the key meeting point for the global cannabis scene. With 60,000 expected visitors, over 500 exhibitors, and an expanded festival area, Mary Jane Berlin will – for the first time since its founding in 2016 – be the largest cannabis trade fair in the world, taking place from June 19 to 22, 2025. On more than 70,000 square meters of exhibition space, industry icons like former world boxing champion Mike Tyson will present the latest products, top acts such as Samy Deluxe will perform on the festival stage, and experts will discuss home cultivation, the booming demand for medical cannabis, and the growing telemedicine market at the professional conference. Cannabis-related sales in Germany are expected to reach around one billion euros in 2025.

“We started as a small scene gathering and are now the largest cannabis trade fair in the world. When it came to cannabis, the world used to look to the U.S. – now it looks to Germany, and Mary Jane is the highlight of the industry,” says Nhung Nguyen, organizer and co-founder of the fair. A record 40,000 tickets were sold in advance. For the first-ever B2B day on June 19, 5,000 industry representatives from 50 countries have registered. The professional conference, organized in cooperation with the Cannabis Industry Association (BvCW), will host 90 high-profile speakers from business, science, and politics. “We want to showcase all facets and the many positive qualities of cannabis – and why legalization is the only right way forward,” says Nguyen.

The effects of legalization are also reflected in the numbers: Germany has around 4.5 million cannabis users, and that number has roughly doubled over the past 15 years. According to Statista, cannabis market revenues in Germany are expected to reach around one billion euros in 2025. Special focus is being placed on medical cannabis. Thanks to the new legal situation, the market is booming like never before. The import of cannabis for medical and scientific purposes has significantly increased over the course of 2024, according to the Federal Institute for Drugs and Medical Devices. The quantity rose from 8.1 tons in Q1 to 11.6 tons in Q2, 20.7 tons in Q3, and 31.7 tons in Q4.

Numerous medical cannabis distributors will showcase their product ranges and services at the fair. In addition, telemedicine is playing an increasingly important role. More and more people are using the option to order cannabis with a prescription online and receive it via a pharmacy. Delivery services bring the products directly to customers. “The medical community is increasingly recognizing the plant’s value in treating illnesses and relieving pain. Initial hesitations from doctors and pharmacies are slowly dissolving,” says Nguyen.

In addition to medical cannabis, visitors will also find the latest industry trends at the fair: digitalized balcony greenhouses for home growing, edibles from brownies to granola bars, and a wide selection of non-intoxicating CBD products ranging from massage oils to meditation teas. “Mary Jane offers something for everyone. We’ve tailored the entire fair concept to attract new audiences as well. Smoking is prohibited in the halls out of consideration for all guests, and there will be various chill-out areas, international food trucks, and awareness teams. Everyone should feel comfortable and have fun,” says Nguyen.

Keep reading